3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Breast Diseases
2
Unilateral Breast Neoplasms
1
Recurrence
1
Osteitis Deformans
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Breast Neoplasms, Male
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Metastatic Breast Cancer
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
2
ribociclib
1
duvelisib
1
Secretin
1
Rituximab
1
NVP-BKM120
1
Letrozole
1
Everolimus
1
CA-19-9 Antigen
1
Aspirin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hereditary Sensory and Autonomic Neuropathies
×
ribociclib
×
Clear all
NCT03439046
2024-08-01
BioItaLEE
Novartis
Phase 3
Completed
287 enrolled